Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study-Reference-Cited by-同舟云学术

Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study

Published:2005-09 Issue:5 Volume:15 Page:785-792
ISSN:1048-891X
Container-title:International Journal of Gynecological Cancer
language:en
Short-container-title:Int J Gynecol Cancer

Author:

GORDON A.N.,FINKLER N.,EDWARDS R.P.,GARCIA A.A.,CROZIER M.,IRWIN D.H.,BARRETT E.

Publisher

BMJ

Subject

Obstetrics and Gynaecology,Oncology

Reference29 articles.

1. Cancer Statistics, 2003

2. Ovarian cancer: Age contrasts in incidence, histology, disease stage at diagnosis, and mortality

3. Ovarian carcinoma diagnosis

4. Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer

Cited by 201 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multifaceted role of erlotinib in various cancer: nanotechnology intervention, patent landscape, and advancements in clinical trials;Medical Oncology;2024-06-12

2. BPTF Drives Gastric Cancer Resistance to EGFR Inhibitor by Epigenetically Regulating the C‐MYC/PLCG1/Perk Axis;Advanced Science;2023-10-20

3. Anlotinib in patients with recurrent platinum resistant/refractory ovarian cancer: a prospective, single arm, phase II study;International Journal of Gynecologic Cancer;2023-09-29

4. Biological and clinical impact of membrane EGFR expression in a subgroup of OC patients from the phase IV ovarian cancer MITO-16A/MANGO-OV2A trial;Journal of Experimental & Clinical Cancer Research;2023-04-11

5. Combined PARP inhibitors and small molecular inhibitors in solid tumor treatment (Review);International Journal of Oncology;2023-01-04